Kailera Therapeutics IPO
Kailera Therapeutics is a biotechnology company focused on developing innovative cancer therapies using novel drug delivery and targeting approaches. The company's pipeline addresses unmet needs in oncology through its proprietary platform technologies.
Key Facts
| Industry | Biotechnology |
| Funding | Raised $625 million through IPO on April 17, 2026, pricing shares at $16 (high end of range); began trading on Nasdaq under ticker KLRA |
About Kailera Therapeutics
Kailera Therapeutics focuses on developing next-generation cancer therapies through innovative drug delivery and targeting mechanisms. The company's approach centers on creating more effective and selective treatments that can improve patient outcomes while reducing side effects commonly associated with traditional cancer therapies.
The company operates in the oncology space with a focus on addressing cancers with high unmet medical need. Kailera's platform technologies aim to enhance the therapeutic index of cancer drugs by improving their delivery to tumor sites while minimizing exposure to healthy tissues, representing a critical advancement in precision oncology approaches.
IPO Status
Kailera Therapeutics successfully completed its initial public offering on April 17, 2026, marking the largest biotech IPO since 2021. The company priced its upsized offering at $16 per share (the high end of its original range) and raised $625 million, significantly exceeding its initial target of $467-533 million. The stock began trading on the Nasdaq under the ticker KLRA and opened at $26 per share, representing a 62.5% surge above the IPO price, with shares continuing to trade over 60% higher throughout the debut day. The company's IPO focuses on its pipeline of injectable and oral obesity drugs, positioning Kailera to compete in the rapidly expanding weight-loss therapeutic market. The strong market reception and record-breaking raise demonstrate significant investor appetite for obesity treatments, with the CEO expressing confidence in the company's positioning ahead of the offering. The successful debut reflects broader momentum in the biotech sector and particular enthusiasm around the weight-loss drug race, as Kailera joins other companies developing next-generation obesity therapeutics.
Competitors
Frequently Asked Questions
Does Kailera Therapeutics have a stock?
No, Kailera Therapeutics has not completed an IPO and remains a private biotechnology company. The company is currently focused on developing its cancer therapy pipeline.
When is the Kailera Therapeutics IPO date?
Kailera Therapeutics has not announced a specific IPO date or timeline. No confirmed details about public offering plans have been disclosed. Sign up for alerts to stay informed.
How can I buy Kailera Therapeutics stock?
Kailera Therapeutics shares are not currently available for purchase as the company remains private. If an IPO occurs, shares would become tradeable through standard brokerage platforms. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts